Windward Bio Group AG (Nasdaq: WWB) is expected to list on 2026-11-13 at a price range of $16.00 to $18.00 per share. The biotech is betting that ultra-long-acting antibody drugs can win in asthma, COPD, and atopic dermatitis.
The bull case is a large respiratory-immunology market and a cash-rich balance sheet; the bear case is that Windward has no approved products and still needs clinical execution to prove its lead programs.
Windward Bio Group AG (Nasdaq: WWB) is expected to list on 2026-11-13 at a price range of $16.00 to $18.00 per share. The biotech is betting that ultra-long-acting antibody drugs can win in asthma, COPD, and atopic dermatitis.
The bull case is a large respiratory-immunology market and a cash-rich balance sheet; the bear case is that Windward has no approved products and still needs clinical execution to prove its lead programs.
Quick Facts
Expected listing date: November 13, 2026
Exchange: NASDAQ
Proposed symbol: WWB
Price range: 16.00 - 18.00
Shares offered: 10.29M shares
Status: Expected
Company Overview
Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for respiratory and dermatologic diseases. Its lead candidate, WIN378, is an anti-TSLP monoclonal antibody in Phase 2/3 asthma and Phase 2 COPD studies. Its second program, WIN027, is a bispecific antibody targeting TSLP and IL-13, with planned later-stage studies. The company has no approved products and no product revenue to date.
The company was incorporated in Switzerland on July 5, 2024 and began operations in January 2025, with a registered office in Basel and a U.S. principal executive office in Dover, Delaware. As of September 30, 2026, it had 38 employees, including 24 in R&D and 17 with Ph.D. or M.D. degrees. The broader market backdrop is attractive but crowded: Windward is targeting asthma, COPD, and atopic dermatitis, where biologics are already a major category and longer-acting dosing could be a meaningful differentiator. The company’s filing points to a competitive field that includes AstraZeneca, Amgen, Sanofi, GSK, Pfizer, Johnson & Johnson, Eli Lilly, and Upstream Bio.
Why They're Going Public
Windward says the IPO proceeds will fund the next stage of its clinical pipeline. The money is earmarked for completion of POLARIS-1 Phase 2/3 asthma and POLARIS-2 Phase 3 asthma for WIN378, completion of the SIRIUS Phase 2 COPD study for WIN378, and completion of planned global Phase 2b COPD and Phase 2 atopic dermatitis trials for WIN027.
The company also plans to use proceeds to advance bispecific programs through IND-enabling studies, with the remainder going to working capital and general corporate purposes. In practical terms, the listing is meant to extend the runway, support multiple late-stage trials, and give Windward the capital base it needs to keep building a pipeline around the TSLP pathway.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Windward is still pre-commercial, so the financial story is about cash burn rather than revenue growth. The company says it has not generated any revenue from product sales to date. It reported $33.3 million of net cash used in operating activities in FY2025 and $25.9 million in H1 2026. Search snippets from the filing also indicate a net loss of $48.3 million in FY2025 and $42.6 million in H1 2026, versus $22.8 million in H1 2025.
The balance sheet is the key support point. As of June 30, 2026, Windward reported $207.3 million in cash, cash equivalents and marketable securities, with total assets of $290.7 million, total liabilities of $25.0 million, and total equity of $265.7 million. A preliminary unaudited estimate in the filing put cash, cash equivalents and marketable securities at about $181.8 million as of September 30, 2026. That gives the company meaningful near-term flexibility, but the burn profile shows this is still a capital-intensive development story.
Risk Factors
The biggest risk is clinical execution. Windward has no approved products, no product revenue, and its value depends on successful development of WIN378 and WIN027. The IPO is funding multiple studies, but trial timing, efficacy, safety, and regulatory review can all change the timeline quickly. If either lead program underperforms, the investment case weakens materially.
There is also financing and dilution risk. The company says it may need additional capital beyond the IPO through equity, debt, or other financing. That matters because biotech development is expensive and the current cash balance, while solid, does not eliminate future funding needs. Investors should also watch competition in TSLP and adjacent respiratory markets, manufacturing and supply-chain execution, intellectual property protection, and the 180-day lock-up on insiders and certain shareholders, which can shape post-listing trading supply.
Comparable Public Companies
The closest public comps are other respiratory and immunology biotech names. Upstream Bio (NASDAQ: UPB) is a relevant TSLP-pathway peer focused on respiratory disease. Apogee Therapeutics (NASDAQ: APGE) is another biologics-focused immunology company. Astria Therapeutics (NASDAQ: ATXS) and Kymera Therapeutics (NASDAQ: KYMR) are also useful reference points for development-stage biotech investors, though their programs are not identical to Windward’s. The common thread is that these are still pipeline-driven companies where valuation depends on clinical data rather than current sales.
On trading backdrop, the comp set looks mixed rather than uniformly hot. Upstream Bio has been down sharply over the last 6 to 12 months, which suggests the market has been selective on respiratory biotech risk. That matters for Windward because it is coming public into a sector where investors want clear differentiation, strong data, and a believable path to late-stage value creation. The IPO is not arriving into a broad commercial biotech story; it is a clinical-stage, data-dependent setup.
Verdict
What to watch as Windward prices is whether investors are willing to pay up for a late-stage respiratory biotech with a sizable cash balance but no approved products yet. The setup favors the company’s story if the market believes WIN378 can stand out in asthma and COPD as an ultra-long-acting TSLP therapy, especially with a large addressable market and a Sanofi-linked strategic placement in the background. The key question is whether the $16.00 to $18.00 range reflects enough optimism for the pipeline without stretching too far ahead of the data.
This IPO lands in a market that still rewards differentiated biotech narratives, but only when the science looks credible and the financing runway is clear. Windward’s angle is timely because it sits at the intersection of a big respiratory-immunology market and a push for longer-acting biologics, yet the company still has to prove that its programs can convert that thesis into clinical and commercial traction. Shareholders should watch the pricing, the implied valuation versus the cash position, and how much demand shows up for a pre-revenue biotech with multiple shots on goal.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
